Despite the promising results, Chipotle’s stock price fell after the report
Chipotle’s
net income came in at $80.2 million, or $2.82 per share. Due to
pandemic-related restructuring costs, the figures came below last year’s $3.47
a share.
Chipotle managed to report sales growth despite the business
being affected by the pandemic. The same-store sales gained 8.3% from the last
year’s figures. The figures topped the 7.3% increase forecasted.
Digital sales reported the most significant increase –
202.5% - to $776.4 million, making up 48.8% of the total quarterly sales.
Overall, the sales totaled $1.6 billion, 14% higher than
last year’s numbers.
Following the report, Chipotle’s stock price lost nearly 5%.
Year-to-date, the company’s stock gained 60%, while USA500 went up 6.6%.
Sources: marketwatch.com
This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.
Previous Article
Ericsson’s Q3 earnings surprise the markets
Next Article
Remdesivir gets FDA's approval